Tue, May 10, 2022

David Lebowitz Maintained (ARQT) at Buy with Decreased Target to $36 on, May 10th, 2022

David Lebowitz of Morgan Stanley, Maintained "Arcutis Biotherapeutics, Inc." (ARQT) at Buy with Decreased Target from $37 to $36 on, May 10th, 2022.

David has made no other calls on ARQT in the last 4 months.



There is 1 other peer that has a rating on ARQT. Out of the 1 peers that are also analyzing ARQT, 0 agree with David's Rating of Hold.



This is the rating of the analyst that currently disagrees with David


  • Uy Ear of "Mizuho" Maintained at Strong Buy with Decreased Target to $57 on, Thursday, April 7th, 2022